Contents lists available at SciVerse ScienceDirect



Journal of Steroid Biochemistry and Molecular Biology

journal homepage: www.elsevier.com/locate/jsbmb



Review Is the metabolism of 25-hydroxyvitamin D₃ age-dependent in dairy cows?

Mirja R. Wilkens^{a,*}, Imke Cohrs^a, Adrian L. Lifschitz^b, David R. Fraser^c, Katharina Olszewski^d, Bernd Schröder^a, Gerhard Breves^a

^a Department of Physiology, University of Veterinary Medicine Hannover, Foundation, 30173 Hannover, Germany

^b Laboratory of Veterinary Pharmacology, Faculty of Veterinary Sciences, B7000 Tandil, Argentina

^c Faculty of Veterinary Science, University of Sydney, NSW 2006 Sydney, Australia

^d DSM Nutritional Products, 4002 Basel, Switzerland

ARTICLE INFO

Article history: Received 25 June 2012 Received in revised form 2 October 2012 Accepted 28 November 2012

Keywords: Dairy cow 25-hydroxyvitamin D₃ Plasma half-life Hypocalcemia Age effect Vitamin D metabolism

ABSTRACT

It has recently been demonstrated that prepartum administered 25-hydroxyvitamin D₃ (25-OHD₃) is a promising candidate to assist the maintenance of peripartal calcium homeostasis in dairy cows. Since the incidence of peripartal hypocalcemia and the reported beneficial effects of the treatment are both associated with the lactation number, we investigated pharmacokinetic aspects of 25-OHD₃ related to the age of dairy cows. The daily oral administration of 3 mg 25-OHD₃ in rapeseed oil as well as a treatment with 4 and 6 mg included in the feed during the last eight to ten days of gestation resulted in linear dosage-and age-dependent increases in plasma 25-OHD₃. After parturition the administration was stopped and blood samples were taken to calculate the plasma half-life. Irrespective of the supplemented dosage, cows starting the 2nd lactation showed a significantly longer plasma half-life of 25-OHD₃ than cows starting the 3rd or higher lactation. Age-dependent differences in the increase of plasma 25-OHD₃ could already be found before parturition when calcium homeostasis was not yet significantly challenged. Additionally, no correlations between plasma half-life of 25-OHD₃ and 1,25-dihydroxyvitamin D₃, PTH or the bone resorption marker CrossLaps were observed after parturition. Thus we conclude that the influence of the lactation number on the pharmacokinetics of 25-OHD₃ is related directly to the age of the cows.

This article is part of a Special Issue entitled 'Vitamin D Workshop'.

© 2012 Elsevier Ltd. All rights reserved.

Contents

1.	Introduction	44
2.	Materials and methods	44
	2.1. Animals, treatments and sampling	44
	2.2. Analytical methods	45
	2.3. Calculations and statistical analyses	45
3.	Results and discussion	45
	3.1. Increase of plasma 25-OHD₃ during daily oral treatment before parturition	45
	3.2. Peripartal parameters of Ca homeostasis and plasma half-life of 25-OHD3 postpartum	
	References	46

1. Introduction

It has recently been demonstrated that prepartum administered 25-hydroxyvitamin D_3 (25-OHD₃) is a promising candidate to assist the maintenance of peripartal calcium (Ca) homeostasis in dairy cows [1]. Since the incidence of peripartal hypocalcemia [2] and the reported beneficial effects of the treatment are both associated

with the lactation number [1], we investigated pharmacokinetic aspects of 25-OHD₃ related to the age of dairy cows.

2. Materials and methods

2.1. Animals, treatments and sampling

Handling, treatment and sampling of the animals were approved and the conduct of the experiment was supervised according to the German Animal Welfare law.

In the 1st series, a total of 14 multiparous dairy cows were individually supplemented orally with 3 mg 25-OHD₃ (Rovimix Hy-D[®],

^{*} Corresponding author. Tel.: +49 511 856 7628; fax: +49 511 856 7687. *E-mail address*: Mirja.Wilkens@tiho-hannover.de (M.R. Wilkens).

^{0960-0760/\$ -} see front matter © 2012 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.jsbmb.2012.11.013

DSM Nutritional Products, Basel, Switzerland) dissolved in rapeseed oil once daily from the 270th day of gestation until parturition. Blood samples were taken every other day from the beginning of the experiment to evaluate the increase in plasma 25-OHD₃.

In the 2nd series 90 cows were divided into three groups. Two experimental groups were provided from the calculated day -10 until parturition (day 0) with either 4 or 6 mg 25-OHD₃ provided in the mineral feed additive, while the remaining 30 cows served as the untreated control group. Blood samples were taken every other day from the beginning of the experiment until parturition and on day 1, day 2, day 4, day 8, day 16 and day 32 postpartum.

2.2. Analytical methods

The concentrations of 25-OHD₃ and 1,25-dihydroxyvitamin D₃ (1,25-(OH)₂D₃) were determined by HPLC by the Analytical Research Center of DSM Nutritional Products (Kaiseraugst, Switzerland). Ionized calcium (Ca²⁺) was determined in whole blood using a blood gas analyzer (Chiron Diagnostics, RapidLab 348, Bayer, Fenwald, Germany). Analyses for parathyroid hormone (PTH) and C-terminal telopeptide of type I collagen (CrossLaps, CL), a marker for bone resorption, were done using commercial kits (Bovine Intact PTH ELISA Kit, Immutopics Inc., San Clemente, CA; Serum CrossLaps ELISA, IDS GmbH, Frankfurt, Germany).

2.3. Calculations and statistical analyses

For the calculation of plasma half-life plasma concentrations of 25-OHD₃ in untreated animals were used as basal values to correct those of supplemented animals. The plasma concentrations versus time curves obtained for each individual animal in each treatment group (starting on day 1 after parturition when no additional 25-OHD₃ was supplemented until day 32 after calving) were analyzed with the PK Solutions 2.0 (Ashland, OH) computer software. Pharmacokinetic parameters were determined using the method of a non-compartmental model. The terminal (elimination) half-life ($t_{1/2}$ el) was calculated as $\ln 2/(z$ where (z is the elimination rate.

Statistical analyses were performed using SPSS 19.0 (SPSS, Chicago, IL). Values are expressed as mean \pm standard error of the mean. The numbers of animals investigated are given in brackets in the figure legends. Linear regression was used to analyze the prepartum increases in plasma 25-OHD₃ during the 1st series. In order to reveal effects of age on the peripartal time courses of plasma parameters we used repeated measurements ANOVA (lactation number and dosage) separately for untreated and HyDsupplemented cows. The Fisher Least Significant Difference (LSD) test was applied for comparison of estimated marginal means at each time point. Calculation of the Pearson product-moment coefficient was used to estimate the dependence between two variables (e.g. 25-OHD₃ half-life and PTH plasma concentration). Plasma half-lives of 25-OHD₃ were compared by two-way ANOVA (lactation number, dosage, interaction) followed by the Bonferroni post-test.

In all cases, *P* values < 0.05 were considered significant.

3. Results and discussion

3.1. Increase of plasma 25-OHD₃ during daily oral treatment before parturition

Fig. 1 shows the linear correlation between the prepartum plasma 25-OHD₃ concentrations and the duration of daily oral treatment with individually administered 25-OHD₃ (3 mg in rapeseed oil). The calculated slopes of the two different lactation




Fig. 1. Increase of plasma 25-OHD₃ during daily oral treatment with 3 mg 25-OHD₃ (1st series). Significant linear correlations can be found in supplemented animals. The slopes for the different lactation number groups differ significantly (P<0.01).

number groups differ significantly (2nd lactation: 16.07 ± 0.87 , \geq 3rd lactation: 12.92 ± 0.69 ; *P* < 0.01).

From these results it can be concluded that either the absorption of 25-OHD₃ is more efficient in younger animals or the rate of elimination is faster in older cows.

3.2. Peripartal parameters of Ca homeostasis and plasma half-life of 25-OHD₃ postpartum

Regardless of whether cows received 25-OHD₃ supplementation or not, the decrease in whole blood Ca²⁺ concentrations at parturition was more pronounced in older cows (2nd lactation: $1.16 \pm 0.08 \text{ mmol } \text{L}^{-1}$; \geq 3rd lactation: $1.07 \pm 0.13 \text{ mmol } \text{L}^{-1}$; Fisher LDS test: P < 0.01). This was accompanied by higher PTH levels on day 1 after parturition (2nd lactation: $105 \pm 19 \text{ pg mL}^{-1}$; \geq 3rd lactation: $202 \pm 46 \text{ pg mL}^{-1}$; Fisher LSD test: P < 0.05) and a sharper increase in 1,25-(OH)₂D₃ concentrations in animals at the 3rd or higher lactations compared to younger cows (data not shown; ANOVA for repeated measurements: P < 0.05). In supplemented cows, plasma 25-OHD₃ concentrations of younger cows were significantly higher during the entire observation period (Figs. 1 and 2; ANOVA for repeated measurements: P < 0.05). An effect of age on CL concentrations could only be found in supplemented cows before parturition (data not shown).

The observation that peripartal hypocalcemia and the respective hormonal responses are more pronounced in older cows is in line with former studies [2]. Immediately after parturition, the higher




Fig. 2. Time courses of plasma 25-OHD₃ after parturition (2nd series), concentrations of supplemented animals corrected with respective values of untreated control animals. Effects of time (P < 0.001), dosage (P < 0.001), lactation number (P < 0.01) and an interaction of dosage and lactation number (P < 0.01) were revealed in supplemented animals using repeated measurements ANOVA. Results of Fisher LSD test for comparison of estimated marginal means are given within the figure.




Fig. 3. Plasma half-lives of 25-OHD₃ in supplemented cows. Two-way ANOVA (dosage and lactation number) revealed an effect of lactation number (P<0.001). Asterisks indicate results of Bonferroni post-test: *P<0.05.

 $1,25-(OH)_2D_3$ concentrations might induce different pathways of vitamin D catabolism [3] and thus, a faster elimination of 25-OHD₃.

However, no correlations between plasma half-life of 25-OHD₃ and 1,25-(OH)₂D₃, peak concentrations of 25-OHD₃, PTH or the bone resorption marker CrossLaps could be found. Plasma half-life of 25-OHD₃ was only positively correlated with basal Ca²⁺ concentrations (0.342; P < 0.01), basal 25-OHD₃ (0.330; P < 0.05), 25-OHD₃ on day 8 postpartum (0.292; P < 0.05), on day 16 (0.409; P < 0.01) and on day 32 (0.579; P < 0.01).

When data of supplemented animals were compared with respect to age it was found that cows starting the 2nd lactation treated with 4 mg daily showed a significantly longer plasma half-life of 25-OHD₃ than cows starting the 3rd or higher lactation (P < 0.01). The same significant difference in plasma half-life could

be observed in animals treated with $6 \text{ mg } 25\text{-OHD}_3$ daily (P < 0.01). Although plasma half-life of animals dosed with 6 mg seemed to be longer compared to the respective 4 mg group, an effect of dosage could not be verified statistically (Fig. 3).

As no impact of the more pronounced hypocalcemia in older cows and the corresponding stronger hormonal response to this challenge could be found, the longer plasma half-life of 25-OHD₃ in younger animals is most probably caused by an age-dependent slower rate of degradation of 25-OHD₃. This could involve a lower expression and/or activity of the 24-hydroxylase of younger animals in comparison to older individuals which has already been demonstrated in the rat [4]. Although this assumption is supported by the positive correlation between the calculated plasma-half life postpartum and the basal concentrations of 25-OHD₃ prepartum when $1,25-(OH)_2D_3$ levels were low, further studies are needed to prove this hypothesis.

References

- [1] M.R. Wilkens, I. Oberheide, B. Schroder, E. Azem, W. Steinberg, G. Breves, Influence of the combination of 25-hydroxyvitamin D_3 and a diet negative in cation–anion difference on peripartal calcium homeostasis of dairy cows, Journal of Dairy Science 95 (1) (2012) 151–164.
- [2] T.A. Reinhardt, J.D. Lippolis, B.J. McCluskey, J.P. Goff, R.L. Horst, Prevalence of subclinical hypocalcemia in dairy herds, Veterinary Journal 188 (1) (2011) 122– 124.
- [3] G.D. Kutuzova, H.F. DeLuca, Gene expression profiles in rat intestine identify pathways for 1,25-dihydroxyvitamin D3 stimulated calcium absorption and clarify its immunomodulatory properties, Archives of Biochemistry and Biophysics 432 (2) (2004) 152–166.
- [4] J.A. Johnson, M.J. Beckman, A. Pansini-Porta, S. Christakos, M.E. Bruns, D.C. Beitz, R.L. Horst, T.A. Reinhardt, Age and gender effects on 1,25-dihydroxyvitamin D3regulated gene expression, Experimental Gerontology 30 (6) (1995) 631–643.